The benzamide derivative entinostat was reported as a class I inhibitor (HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM, respectively) that demonstrated preclinical and Phase II clinical efficacy in ER+ BC with an unclear mechanism of action [17,18]. The gene discussed is HDAC3; the disease is breast cancer.